Akero Therapeutics Inc
Change company Symbol lookup
Select an option...
AKRO Akero Therapeutics Inc
ILMN Illumina Inc
GOLD Barrick Gold Corp
CLPS CLPS Inc
SIOX Sio Gene Therapies Inc
NSTB Northern Star Investment Corp II
ALKS Alkermes Plc
CPTNW Cepton Equity Warrant Exp 10th Feb 2027 *W EXP 02/10/2027
APPF Appfolio Inc
FMN Federated Hermes Premier Municipal Inc
Go

Health Care : Biotechnology | Small Cap Growth
Company profile

Akero Therapeutics Inc. is a clinical-stage company that develops transformational treatments for patients with serious metabolic diseases. The Company is engaged to treat non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate, efruxifermin (EFX), is an analog of fibroblast growth factor 21 (FGF21), which is a hormone that protects against cellular stress and regulates the metabolism of lipids, carbohydrates and proteins throughout the body. EFX is being evaluated in two Phase IIb clinical trials in patients with biopsy-confirmed NASH: the study in pre-cirrhotic patients with F2-F3 fibrosis and the SYMMETRY study in cirrhotic patients with compensated F4 fibrosis. Its EFX program is focused on patients with cirrhotic NASH (F4, compensated) in Phase IIb clinical trial.

Price
Delayed
$46.03
Day's Change
-0.77 (-1.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
47.18
Day's Low
45.81
Volume
(Light)

Today's volume of 33,329 shares is on pace to be much lighter than AKRO's 10-day average volume of 440,890 shares.

33,329
Latest Earnings Missed Consensus (Q3 ending 09/2022)Next Earnings Announcement
Q3
Announced November 4, 2022
-$0.92Q3 Consensus
of 5 analysts
-$0.74Difference from
consensus
-24.66%
Q4 Earnings
will announce
(Unconfirmed) February 23, 2023

Quarterly Earnings History and Estimates

Show high-low estimates
Draw trendlines

Draw up to 3 lines inside the chart.

Display:

UpdateCancel

AKRO's fiscal year ends in December

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Information provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.